PropertyValue
nif:beginIndex
  • 0 (xsd:integer)
nif:broaderContext
nif:endIndex
  • 225 (xsd:integer)
nif:isString
  • More than 90% of patients treated with vemurafenib experience AEs; 26% of them develop grade 3-4 skin toxicity.7 19 We documented a severe lymphopenia in our patient as early as 2 days after initiation of anti-BRAF treatment.
rdf:type